Adcendo secures $75m in Series C funding for ADC development
Funding will enable progress on the ADCE-T02 Phase I Tiffany-01 cohort expansion in a range of solid tumours.
Drug Development
Lilly to acquire CrossBridge Bio for up to $300m
Travere Therapeutics gains FDA approval for sparsentan in FSGS
MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority
Telix and Regeneron sign $4.3bn deal to co-develop radiopharmaceutical therapies
Roche and C4 Therapeutics to advance degrader-antibody conjugates research
Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation
EverSea Medicines to acquire Hasten Biopharmaceuticals
